PHARMACEUTICAL INDUSTRY SYMPOSIUM 2 BY ZENTIVA
Daruph - Added Value Dasatinib in treatment of Leukemia
Chronic myeloid leukemia (CML)- disease overview and Tyrosine kinase inhibitors (TKI) differentiation
Prof.LIdija Cevreska- University Clinic for Hematology-Skopje, R.N.Macedonia
Daruph (Dasatinibe anhydrous) for the treatment of chronic myeloid leukemia - Focus on clinical pharmacokinetics and pharmacodynamics
Ass.Nevenka Ridova- University Clinic for Hematology-Skopje, R.N.Macedonia